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ABSTRACT 
 
Inflammatory bowel disease (IBD) with its two most common entities, ulcerative colitis and 
Crohn’s disease, causes an increased risk of developing intestinal cancers. In fact, 
malignancies are the second most common cause of death after cardiovascular diseases in 
both genders of patients with IBD. Risk factors for colorectal cancer in IBD correlate with the 
duration of the disease, extent of disease, the association with primary sclerosing cholangitis, 
family history, and early age at onset. Patients with IBD also have an increased risk for 
developing a variety of extra-intestinal malignancies. In particular, lymphomas, mostly non-
Hodgkin lymphomas and skin cancers, are more frequently observed in IBD patients. 
Longstanding inflammation and the degree of immunosuppression as a result of IBD 
treatment appear to be the main driving factors for IBD-related carcinogenesis. This review 
provides an update on the clinical and pathological features of IBD-related intestinal and 
extra-intestinal malignancies. 
 
 
Key words: Inflammatory bowel disease; Ulcerative colitis; Crohn’s disease; Dysplasia; 
Colorectal cancer; Cholangiocarcinoma; Lymphoma. 
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INTRODUCTION 
 
Inflammatory bowel disease (IBD), including ulcerative colitis (UC) and Crohn’s disease 
(CD), is a life-long immune-mediated chronic inflammatory disorder of the gastrointestinal 
tract. Both types of IBD are characterized by chronic inflammation with episodes of 
remission and relapses [1,2]. It is estimated that at least 0.4% of Europeans and North 
Americans live with inflammatory bowel disease [2]. IBD patients are associated with excess 
deaths from infection, cardiovascular diseases and cancers [3]. Malignancies are the second 
most common cause of death after cardiovascular diseases in both men and women with IBD 
[4]. 
 
IBD patients are at increased risk of developing carcinoma of the gastrointestinal tract, 
including colorectal carcinoma and small bowel adenocarcinoma. Both CD and UC carry an 
increased risk with the greater risk associated with UC. More recently, patients with IBD 
have also been shown to be at increased risk of developing extra-intestinal malignancies, such 
as lymphomas and skin cancers. This article focuses on the clinical and pathological features 
of IBD-related intestinal and extra-intestinal malignancies. 
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GASTROINTESTINAL MALIGNANCIES ASSOCIATED WITH IBD 
 
IBD-related colorectal cancer 
 
Increased risk of intestinal cancers in IBD patients have been identified in studies of 
population-based registries, nationwide cohorts and referral-center cohorts [1,5-8]. 
 
A meta-analysis of 116 studies by Eaden et al showed that the prevalence of colorectal cancer 
in patients with UC is approximately 3.7% [9]. The development of cancer accounts for one 
third of deaths related to UC. The risk begins to rise significantly above that of the general 
population approximately 8-10 years after diagnosis. Meta-analyses showed that the risk is 2% 
at 10 years, 8% at 20 years, and 18% at 30 years after onset [8,10]. Patients with more 
extensive bowel disease are at greater risk; the incidence of colorectal cancer in UC patients 
with extensive colitis (pancolitis) is 19 times higher than the general population compared to 
4 times higher if the disease is limited to left-side colon only. The risk for colorectal cancer in 
patients with CD appears lower than patients with UC. However, Crohn’s patients have a 
higher risk of developing small bowel adenocarcinoma compared to the general population [8, 
11]. 
 
Due to a high prevalence of primary sclerosing cholangitis in IBD patients (particularly in 
UC patients), hepatobiliary cancers, especially cholangiocarcinoma, have been linked to IBD 
[12,13]. In such cases, those who have primary sclerosing cholangitis are at an even greater 
risk for colorectal cancer, and that increased risk is readily present at the onset of disease 
[14]. 
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On average, patients with IBD who are diagnosed with colorectal cancer are younger than 
non IBD-related colorectal cancer patients. A family history of colorectal cancer is associated 
with a 2 to 3-fold risk of colorectal cancer in the general population. This risk is also seen in 
patients with UC. Like non-IBD patients, the overall survival for IBD -related colorectal 
cancers is driven primarily by age, co-morbidities, and cancer stage at diagnosis [14]. 
 
Pathogenesis of IBD-related colorectal cancers 
 
Although similarities exist in the pathogenesis of IBD-associated and sporadic colorectal 
cancers, there are also many differences. Sporadic colorectal cancers develop via the classic 
adenoma-dysplasia-carcinoma sequence, in which loss of adenomatous polyposis coli (APC)  
gene function is considered the crucial first step that sets the stage for other molecular 
alterations, with TP53 mutations driving the later stages of carcinogenesis [8,15]. IBD-
associated colorectal carcinogenesis also follows a multistep process from inflamed, 
regenerative epithelium, to hyperplastic epithelium, to flat dysplasia, and finally invasive 
adenocarcinoma. However, loss of APC function is much less frequent and usually occurs 
late in the colitis-associated dysplasia-carcinoma sequence [8,15]. Instead, mutation of p53 
and chromosomal instability are relatively early events in IBD-associated cancer [8,15]. 
 
It is thought that the inflammatory process in IBD leads to oxidative stress-induced DNA 
damage of the affected mucosa [16,17]. Methylation of CpG islands in several genes seems to 
precede dysplasia, and is more widespread throughout the mucosa of patients with UC, hence 
this molecular change may represent one of the important genetic alterations in IBD-
associated colon cancer [18]. Constant attempts at regeneration of the damaged 
gastrointestinal mucosa at areas of inflammation provide more opportunities for transcription 
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errors and the subsequent development of neoplasia via activation of procarcinogenic genes 
and inhibition of tumor suppressor genes [18-22].  
 
Alteration in the colonic flora has also been proposed as a mechanism for increased cancer 
risk. Altered flora may increase the degree of inflammation, or possibly produce 
procarcinogenic substances [21,22]. Bacteroides fragilis and Enterococcus feacalis have been 
implicated as procarcinogens [21-23]. Disruption of intestinal homeostasis and aberrant 
immune responses to commensal bacteria lead to IBD. Recent data data suggest a critical role 
of the interaction between the commensal gut bacteria and the immune system orchestrated 
by CTLA-4, at the origin of ipilimumab-induced enterocolitis [24]. This is one of the most 
severe immune-related adverse events observed with anti-CTLA-4 immunotherapy. 
Accordingly, ipilimumab provokes diffuse inflammation of the gastrointestinal tract, causing 
diarrhea, high rate of colonic ulcerations, extensive colitis, and steroid failure. These 
presentations strikingly mirror naturally occurring inflammatory bowel disease. However, 
unlike what is seen in conventional IBD, endoscopic biopsies from ipilimumab-induced 
enterocolitis showed acute, not chronic inflammation [24]. Notably, immunotherapy has 
reached center stage in treatment of advanced cancers including melanoma, non-small-cell 
lung cancer (NSCLC), renal cell carcinoma, bladder cancer and gastrointestinal carcinomas. 
Ipilimumab-induced IBD-like enterocolitis may become a challenging problem for 
oncologists and gastroenterologists. 
 
The use of immunosuppressant to treat inflammatory bowel disease plays a role as well. 
Medical therapies that diminish the intestinal mucosal inflammatory response represent the 
foundation of treatment in IBD. However, prolonged immunosuppression may also increase 
the risk of cancer and allow neoplasia to advance at a faster rate [23,25]. In transplant 
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recipients, the use of thiopurines is associated with a high rate of cancer recurrence, 
particularly within the first two years following transplantation [26]. In patients with IBD, 
limited data suggest that no dramatic incidence of cancer recurrence is associated with the use 
of thiopurines or anti-TNF agents. However, there is a rationale for a two-year drug holiday 
from immunosuppressants after the diagnosis [27]. In addition to concerns about the 
development of de novo cancer in an IBD patient without a history of cancer, clinicians 
caring for patients with IBD are increasingly challenged with questions about IBD 
management after the development of cancer. Conversely, oncologists are often concerned 
about how to manage IBD in cancer patients. To make a most relevant, personalized 
treatment decision, gastroenterologists and oncologists need to work closely on a case by case 
basis and be aware of the potential impact of immunosuppressive drugs on cancers as well as 
of the epidemiology of the risk of developing a second malignancy in cancer survivors.  
 
Colitis-associated dysplasia and dysplasia-associated lesion/mass (DALM) 
 
Both sporadic and colitis-associated colorectal cancer arise from dysplastic precancerous 
lesions, but the morphology and timing of many of the proposed factors are distinct enough to 
classify the colitis-associated colorectal carcinoma as a unique entity [15,18,23,25]. 
 
Histologically, dysplasia is separated into 4 distinct categories: negative for dysplasia, 
indefinite for dysplasia (Figure 1), low grade dysplasia (LGD) and high grade dysplasia 
(HGD) (Figure 2). Among pathologists, there appears to be a high level of agreement on 
both negative for dysplasia and HGD, while the diagnoses of LGD or indefinite for dysplasia 
often have less agreement rate [15,28,29].  
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From an endoscopic (gross) point of view, colitis-related dysplasia may be classified as flat 
or elevated (raised) [30,31]. Flat dysplasia refers to endoscopically undetectable lesions, 
whereas raised dysplasia refers to plaque or polypoid mucosal appearance. Raised dysplastic 
lesion with an appearance of sporadic adenoma has been termed dysplasia-associated lesion 
or mass (DALM) [15,29,30] (Figure 3). Practically, the colitis-associated dysplasia often 
occurs in ill-defined flat mucosa, being detected on taking random biopsies rather than by 
identification of these lesions via endoscopic imaging [30,31].  
 
Owing to extensive inflammation, epithelial regeneration and dysplasia may be difficult to 
distinguish endoscopically and histologically (Figure 4). In many instances, biopsies and 
endoscopic mucosal resections of polypoid mucosal lesions turned out to be inflammatory 
pseudopolyps without dysplasia. Moreover, a patient with IBD can develop a sporadic 
adenoma with HGD, as can any other patient. The pathological differential diagnosis between 
DALM and sporadic adenoma is difficult [15,29,30]. The lesions should be differentiated by 
combined analysis of histological growth pattern and gross appearance. In general, a 
dysplastic lesion without proper delineation to the surrounding mucosa that occurs in long 
standing IBD most likely represents DALM. Colitis-related dysplasia tends to be multifocal 
and is associated with a high cancer risk, up to 43-58%. 
 
If the lesion can be completely resected, and surrounding mucosal biopsies are normal 
without evidence of dysplasia, the lesion may be considered more likely to be sporadic and 
managed in a fashion similar to that of non-IBD patients. Therefore, whenever an actual mass 
or polyp is identified and removed from IBD patient, biopsies of normal-appearing mucosa 
around the lesion should be obtained [28-32]. 
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Colitis-related dysplasia may occur in any part of the colon, can be unifocal or multifocal, 
and cancer is often detected in the same area as the dysplasia [15,29,30]. Mucosal-mapping 
studies indicate that the chronically inflamed colonic mucosa of patients with inflammatory 
bowel disease undergoes a “field change” of cancer-associated molecular alterations before 
there is any histological evidence of dysplasia [33]. This suggests that the chronically 
inflamed colonic mucosa is primed to develop multifocal precancerous and cancerous 
changes. IBD-related colorectal cancer has a higher rate of synchronous and metachronous 
tumors [32,33]. Therefore, patients with DALM are recommended to undergo prophylactic 
proctocolectomy with ileoanal pouch. In contrast, the sporadic adenomas in IBD patients that 
are similar to those observed in non-IBD patients and which are treated by standard 
polypectomy [30,31]. 
 
Surveillance and prevention of colitis-related colorectal cancers 
 
As IBD-related colorectal cancer in most instances develops from dysplasia, it serves as the 
best marker of cancer risk in patients with IBD [34,35]. Although it is readily detectable for 
an advanced tumor endoscopically (Figure 5), the precancerous and early cancer lesions are 
often flat and hard to be identified from an inflamed and distorted background. Diagnosis of 
colitis-associated dysplasia and early cancer is one of the big challenges in gastrointestinal 
endoscopy [34,35].  
 
Multiple societies including the American Gastroenterology Association [36], the American 
College of Gastroenterology (ACG) [37], the American Society for Gastrointestinal 
Endoscopy (ASGE) [38], the SCENIC group [39], European group [40] and the British 
Gastroenterology Society (BSG) [41] have published recommended surveillance guidelines, 
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although they are all quite similar. These recommendations are based on disease duration and 
extent of disease. Colonoscopy screening should start 8 to 10 years after diagnosis, with 
colonoscopies performed every 1 to 2 years with pancolitis and after 15 years in patients with 
left-sided disease only, because the incidence of colorectal cancer increases after 8 years of 
disease. Biopsies should be taken in 4 quadrants every 10 cm, typically resulting in more than 
30 biopsy specimens for histological assessment. 
 
Newer endoscopic techniques, especially high-definition white-light colonoscopy and 
chromoendoscopy with mucosal dye-spraying, allows for the identification of abnormal-
appearing mucosa and has been demonstrated to detect neoplasia at double the rate of 
standard white-light colonoscopy [39]. Therefore, some authorities have recommended using 
chromoendoscopy rather than standard white light colonoscopy to perform targeted rather 
than random biopsies [35,39]. For example, in a study by Rutter and colleagues [42], 100 
patients with long-standing UC underwent 2 colonoscopic examinations back-to-back, i.e., a 
conventional colonoscopy followed by a second colonoscopic examination with 
chromoendoscopy using dye-spraying, with the goal of increasing the detection rate of subtle 
lesions. The authors found a total of 114 additional abnormalities detected in 55 patients 
using chromoendoscopy compared to conventional colonoscopy. Of these 114 abnormalities, 
7 were dysplastic lesions. The authors concluded that a targeted biopsy examination with 
chromoendoscopy required fewer biopsies but, more importantly, detected 9 dysplastic 
lesions, 7 of which were visible only after chromoendoscopy. Moreover, this study suggested 
that a careful examination by chromoendoscopy with targeted biopsies may be more of an 
effective surveillance strategy than obtaining multiple random, non-targeted biopsies. 
Although more longitudinal studies are needed to compare the outcome of surveillance 
techniques, in the coming years, we anticipate that the newer endoscopic techniques move us 
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closer to a surveillance model that is targeted, has high sensitivity and specificity, and allows 
for real-time diagnosis and intervention [43]. 
 
Regular dysplasia surveillance colonoscopy remains the key element to decrease the risk of 
IBD-related colorectal cancers. The anatomic extent of disease and duration of IBD have long 
been held to be risk factors for colorectal cancer in chronic colitis, and recently some special 
risk groups have been identified which may require either more intensive surveillance or 
alternative approaches to cancer prevention. These include patients with primary sclerosing 
cholangitis, age at onset of disease, disease activity and patients with first-degree relatives 
with sporadic colon cancer. There is an emerging interest in potential chemopreventative 
strategies in both sporadic and colitis-associated colorectal cancer [44]. There also have been 
suggestive data that chronic maintenance 5-aminosalicylate use might reduce the risk of 
developing colorectal cancer. Recent data have suggested some potential preventative benefit 
of using ursodeoxycholic acid in patients with ulcerative colitis and primary sclerosing 
cholangitis [44]. 
 
Crohn’s disease and small-bowel adenocarcinoma 
 
Because CD also affects the small intestine, it is associated with increased rates of small 
bowel adenocarcinoma. Fortunately, this more aggressive cancer is not common in the 
general population, but patients with CD have a 20- to 30-fold risk of development of small 
bowel cancer. IBD-related small bowel cancer typically arises in the ileal lesions of patients 
with CD more than 8 years after diagnosis. Prolonged duration of stricturing disease has been 
associated with the development of small-bowel cancer in patients with CD [45-47]. It is 
often associated with previous or synchronous ileal dysplasia, which suggests that it may 
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complicate chronic ileal inflammation in CD through a dysplasia-carcinoma sequence similar 
to that seen in colorectal carcinoma [48].  
 
IBD-related intestinal lymphoma 
 
The risk of primary intestinal lymphomas is significantly higher in patients with IBD, but the 
absolute risk is low (0.1 per 1000 patient-years) [49]. The IBD-related intestinal lymphomas 
are mainly B-cell non-Hodgkin’s lymphomas, typically arising in chronically inflamed 
intestinal lesions of middle-aged men with CD after 8 years of disease [49].  Epstein-Barr 
virus (EBV) is frequently identified in lymphoma cells, which suggests that local 
inflammation and use of immunosuppressant may play a role in these cases by promoting 
EBV infection and replication [50]. 
 
IBD and anal cancers 
 
Anal cancers may arise in the fistulae of patients with long-standing (>10 years) fistulating 
perianal CD, with an incidence rate of approximately 0.2 per 1000 patient-years [51]. These 
cancers include adenocarcinoma and squamous cell carcinoma. Diagnosis is often delayed 
because of a nonspecific clinical presentation and because access to lesions is obscured by the 
presence of stenosis. Although immunosuppression after organ transplantation promotes 
human papillomavirus (HPV)-related anal carcinoma, the risk in patients with IBD who are 
receiving immunosuppressant treatment is unknown.  
 
Primary sclerosing cholangitis and cholangiocarcinoma in IBD patients 
 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
13 
 
Primary sclerosing cholangitis (PSC), a progressive cholestatic disease, is strongly associated 
with UC and to a lesser extent CD. Approximately 70%-80% of patients with PSC have 
concomitant IBD and about 1.4%-7.5% of patients with IBD will develop PSC [12-14]. PSC 
is characterized by progressive inflammation of the intrahepatic and extrahepatic bile ducts 
followed by fibrosis and in worst cases biliary cirrhosis with portal hypertension and liver 
failure (Figure 6). The most concerning complication of sclerosing cholangitis is the 
development of cholangiocarcinoma. 
 
Cholangiocarcinoma occurs at a younger age in IBD patients than in the general population 
without IBD (56 years vs. 71 years, respectively). In Western countries, cholangiocarcinoma 
occurring in patients younger than 40 years old is almost always associated with IBD [12-14]. 
Notably, patients with PSC are also at increased risk of developing colorectal carcinoma. The 
overall survival rate of IBD-related cholangiocarcinoma is low because many patients present 
with unresectable or metastatic disease. Even in patients undergoing aggressive surgery, five-
year survival rates are around 10-40%. 
 
Cholangiocarcinoma is a form of adenocarcinoma arising from the epithelium lining the 
biliary ducts (Figure 6). It can occur in the small bile ducts within the liver, the big branches 
in the center of the liver (hilum) or in the main or common bile duct outside the liver. Similar 
to the development of IBD-related colorectal carcinoma, PSC-associated cholangiocarcinoma 
appears to follow a dysplasia-carcinoma sequence [12,14]. The molecular mechanisms of 
carcinogenesis in PSC are not well elucidated yet. The evolution from PSC to 
cholangiocarcinoma may result from DNA damage by biliary inflammation and bile acids in 
IBD patients with altered DNA repair functions [52,53]. 
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Diagnosis of cholangiocarcinoma in PSC often requires a combination of imaging studies 
performed when clinical deterioration, such as worsening of jaundice, weight loss and 
abdominal pain, suddenly develops [54]. Magnetic resonance imaging (MRI) coupled with 
magnetic resonance cholangiography is generally considered the first-line investigation for 
the malignant transformation, while ultrasound examination seems to have better accuracy in 
discriminating cholangiocarcinoma from underlying PSC. Liver functional test, 
complemented by serological CA19-9 assessment at annual intervals may be recommended. 
Currently, there is no effective medical therapy that alters PSC disease progression. This may 
be partially explained by both the rarity of the disease, which makes it difficult to enroll 
enough patients for study designs of sufficient power, and the poor knowledge of the 
pathogenesis of the disease.  Several agents have been proposed for the treatment of PSC. 
The best-known agent ursodeoxycholic acid that improves hepatobiliary secretion, has 
immunomodulatory properties, and has been associated with biochemical and histological 
improvements in PSC patients [54]. 
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EXTRA-INTESTINAL MALIGNANCIES ASSOCIATED WITH IBD 
 
Early and sustained healing of intestinal inflammation has become the ultimate objective of 
treatment in IBD. Immunosuppressant therapies, including thiopurines, anti-tumor necrosis 
factor, cyclosporine and methotrexate are frequently necessary for IBD management. 
Immunosuppressant may be carcinogenic by directly altering cellular DNA, impairing 
immune control of chronic infection by mutagenic viruses, or reducing immunosurveillance 
of tumor cells [55-57].  After adjusting for confounders, use of thiopurines in IBD has been 
shown to be associated with an overall relative risk of cancer of 1.3 to 1.7 in adequately 
powered cohort studies [55,56]. This excess risk is reversible after thiopurine withdrawal. 
Overall, cancers caused by immunosuppressive drugs represent a minority of the incident 
cancers observed in patients with IBD.  
 
IBD and hematological malignancies 
 
IBD patients show a trend towards higher risks of developing hematological malignancies. 
Compared with the general population, UC patients are significantly more likely to develop 
leukemia, with a standardized incidence rate of 2.0 (95% CI: 1.31 - 3.06) [57,58]. In CD 
patients, there is an increased risk for lymphoma, especially non-Hodgkin lymphoma, with a 
standardized incidence rate of 1.42 (95% CI 1.16 - 1.73) [58].  
 
Thiopurines were shown to increase the incidence of non-Hodgkin’s lymphoma after kidney 
transplantation [59]. Similar observations have been reported in patients with IBD [60,61]. 
Most of the thiopurine-promoted lymphomas are post-transplant-like EBV-associated B-cell 
lymphomas [50]. In these patients, non-Hodgkin’s lymphoma is attributed to the cytotoxic 
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effects of thiopurines on EBV-specific immune cells that prevent the proliferation of EBV-
infected B lymphocytes. Therefore, EBV infection may have an intermediate role between 
immunosuppressive treatment and lymphoma [50].  
 
Patients with IBD exposed to thiopurines are also at increased risk of hepato-splenic T-cell 
lymphoma and post-mononucleosis lymphoproliferative disorder [60-62].  
 
Skin cancers 
 
Patients with IBD receiving immunosuppressive treatment are at increased risk of skin 
cancers [63]. The risk of non-melanoma skin cancer is notably increased in patients receiving 
thiopurines; the incidence rate ratio is 1.64 (95% CI: 1.51-1.78) [63-65]. Squamous 
carcinoma and basal cell carcinoma are the most common non-melanoma skin cancers 
diagnosed in IBD patients. 
 
In contrast, the risk of melanoma in patients with IBD who were exposed to TNF-α 
antagonists has been reported to be 1.5 to 2 times higher than that in patients who were not 
exposed, which represents an incidence rate of 0.5 per 1000 patient-years [60,66]. 
 
The carcinogenic action of thiopurines could include an increased toxicity of ultraviolet A 
radiation on epithelial skin cells and a direct mutagenic effect on the gene encoding PTCH 
[60]. Given the excess risks of skin cancers associated with both IBD and the drugs used to 
treat it, specialists recommend all patients with IBD should practice sun protection and skin 
cancer surveillance from the time of diagnosis.  
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Cervical intraepithelial neoplasia and cervical cancer 
 
It is known that immunosuppression results in a higher incidence of cervical intraepithelial 
neoplasia (CIN) compared with healthy control females [67,68]. The incidence of abnormal 
Papanicolaou smear in IBD women is 42.5% vs. 7% in controls (P < 0.001). In addition, 
women with IBD are more likely to have higher-grade lesions than controls (P < 0.001) [67].  
 
There is a strong correlation between HPV and cancer of the cervix and anogenital regions. 
Immunosuppressant therapies for IBD patients decrease the activity and competence of the 
immune system and may increase the risk to HPV infection. It is currently recommended that 
all women with IBD, particularly those receiving immunosuppressant, strictly adhere to a 
screening program of cervical surveillance and undergo vaccination against HPV, when 
appropriate. 
 
Urinary tract cancers 
 
Transplant recipients receiving immunosuppressive regimens that include thiopurines are at 
increased risk for kidney and bladder cancer [59]. As compared with patients with IBD who 
had never taken thiopurines, patients who were currently using azathioprine were reported in 
a Danish registry study to have a higher incidence of urinary-tract cancers, whereas former 
users of azathioprine did not [56]. 
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SUMMARY 
 
Patients with IBD, including ulcerative colitis and Crohn’s disease, are at increased risk of 
developing intestinal and extra-intestinal cancers. IBD-related malignancies are the second 
most common cause of death in both genders of UC and CD patients. The risk for 
development of intestinal carcinomas in patients with UC and CD appears to depend on the 
duration of disease, the severity of disease, family history of colorectal cancer, and the 
presence of PSC. The colorectal cancer risk begins to rise significantly above that of the 
general population 8-10 years after diagnosis. Therefore, patients with IBD should be 
monitored via an intensive surveillance program. This surveillance program should include 
colonoscopies every 1 to 2 years with multiple biopsies taken from the affected intestine. 
Diagnosis of colitis-associated dysplasia and cancer is one of the big challenges in 
gastrointestinal endoscopy, which might be improved by new endoscopic imaging techniques 
such as high-definition white-light colonoscopy and chromoendoscopy with mucosal dye-
spraying. Table 1 summarizes the clinicopathological features of IBD-related colorectal 
cancers and surveillance recommendations in comparison with sporadic and hereditary 
carcinomas [69-73]. 
 
Patients with IBD have also been shown to be at increased risk of developing extra-intestinal 
malignancies, such as lymphomas and skin cancers. Clinicians who at the front line in the 
management of IBD patients must keep in mind that IBD may be associated with extra-
intestinal malignancies, especially in patients who have longstanding immunosuppressive 
therapies. Guidelines and recommendations including educating patients in self check and 
preventative measurements like sun protection should be developed and applied in clinical 
practice to minimize the risk of IBD-related extra-intestinal malignancies. 
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Prolonged chronic inflammation is assumed to underlie the cause of colitis-associated 
gastrointestinal carcinomas, with oxidative stress-induced DNA damage resulting in the 
activation of procarcinogenic genes and silencing of tumor-suppressor pathways. Further 
studies on colitis-associated dysplasia and carcinoma can help to elucidate the important role 
of the immune system and microbiota in the development of these malignancies. The degree 
of immunosuppression generated from anti-inflammatory treatment appears to be the main 
driving factors for IBD-related extra-intestinal malignancies. 
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Table 1. Clinicopathological features and surveillance recommendations of sporadic, IBD-related and hereditary colorectal carcinomas (CRCs) 
 Sporadic CRCs IBD-related CRCs Hereditary CRCs 
 
Clinicopathological 
features 
• Sporadic CRC accounts for 70 percent of 
all colorectal cancer cases. It is caused by 
an accumulation of sporadic gene 
mutations acquired throughout life. 
Because it takes long time for a series of 
genetic mutations to accumulate, 
sporadic colorectal cancer tends to occur 
at a later age, typically after the age of 
50. 
• Adenoma–carcinoma sequence is a well-
established tumor progression model as a 
result of genetic mutations or other 
chemical modifications, causing 
inactivation or promotion of specific 
genes known as tumor suppressor and 
tumor promoter genes. 
• A stepwise progressive transformation 
can be seen in an adenoma with low 
grade dysplasia to high grade dysplasia 
and early invasive carcinoma (malignant 
polyp). 
• Commonly left sided, with a recent trend 
of right shift as age progresses 
• Inflammatory bowel disease (IBD) related 
malignancies are the second most common 
cause of death in both genders of IBD patients. 
• Both sporadic and colitis-associated colorectal 
cancer arise from dysplastic precancerous 
lesions, but the morphology and timing of 
many of the proposed factors are distinct 
enough to classify the colitis-associated 
dysplasia/mass and IBD-related cancers as 
unique entities. 
• IBD-related colorectal cancer has a higher rate 
of synchronous and metachronous tumors. 
• Colitis-associated dysplasia/mass and IBD-
related cancer may occur in any part of the 
colon. The lesions can be unifocal or 
multifocal, and cancer is often detected in the 
same area as the dysplasia. 
 
• Recognized hereditary syndromes, such 
as familial adenomatous polyposis 
(FAP) and Lynch syndrome [69,70], 
account for up to 5% of cases of 
colorectal cancer.  They are associated 
with germline mutations of genes, 
which predisposes the patient to a high 
risk of CRCs.  Patients with these 
syndromes have a family history of 
colorectal cancer, presenting at an early 
age. 
• Lynch syndrome is the most common 
hereditary colon cancer syndrome. It 
accounts for 3-5% of all colorectal 
cancer cases. CRCs in Lynch syndrome 
tend to be mucinous, right sided 
colonic location and poor 
differentiation with signet ring cells. 
Another striking pathological feature is 
a high density of tumor-infiltrating 
lymphocytes. Despite poor histological 
differentiation, the biological behavior 
of these CRCs is less aggressive. 
• FAP accounts for 1 percent of all CRC 
cases.  Patients with FAP develop 
hundreds to thousands of adenomas, 
usually starting in the teens. These 
polyps can be seen in any part of the 
colon and rectum. 
 
Molecular genetics  • Dysplasia-carcinoma sequence involving 
chromosomal instability, microsatellite 
• Inflammation-dysplasia-carcinoma sequence 
involving chromosomal instability, 
• Lynch syndrome is an autosomal 
dominant disorder, caused by a 
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instability and hypermethylation.  
• Most sporadic colorectal cancers arise 
from an adenomatous precursor lesion 
that progresses through various stages 
until it becomes carcinoma. Loss of APC 
gene function is considered the crucial 
first step that sets the stage for other 
molecular alterations, with p53 mutations 
driving the later stages of carcinogenesis. 
• Mutations in genes such as KRAS, 
NRAS, BRAF and MMR have linked to 
the pathogenesis of CRCs, and these 
molecular markers have become 
increasingly important in prediction of 
response to chemotherapy and 
immunotherapy. 
 
microsatellite instability and hypermethylation.  
• Like sporadic CRCs, IBD-related CRCs are a 
consequence of sequential episodes of 
biological and molecular alterations, including 
immune response by mucosal inflammatory 
mediators, oxidative stress, and intestinal 
microbiota, leading to inflammatory damage, 
regeneration, dysplasia and carcinoma. 
• Precancerous/dysplastic lesion arises in the 
colitic mucosa and progresses through various 
grades of dysplasia. 
• Although many of the molecular alterations 
seen in sporadic CRCs occur in colitis-
associated cancer, the timing and sequence of 
events often differs. For example, mutations in 
p53 gene or a loss of p53 function are seen 
early, whereas the loss of APC gene function is 
a late and less common event. 
germline mutation in one of the 
mismatch repair (MMR) genes: MLH1, 
MSH2, MSH6 and PMS2 [69]. 
• Mutations in these genes results in 
defective DNA mismatch repair, 
leading to microsatellite instability, 
hypermutation and increased risk of 
developing malignant neoplasms.  
• Recent studies suggest that CRCs with 
a defect MMR are sensitive to 
checkpoint blockage drugs and 
microsatellite instability-high 
phenotype is a predictive biomarker for 
checkpoint immunotherapy [71]. 
• FAP is caused by mutation of 
adenomatous polyposis coli (APC) 
gene [70]. Most people inherit the 
genetic abnormality from a parent. But 
in about 25% of cases, the genetic 
mutation occurs spontaneously. 
Cancer risks • Cancer risk increase with aging and 
unhealthy lifestyle.  
• In addition, risk increase with previous 
detection of colorectal adenomas and 
number of adenomas. 
• Risk factors for IBD-related CRCs correlate 
with the duration of the disease, extent of 
disease, the association with primary sclerosing 
cholangitis, family history, and early age at 
onset.  
• Meta-analysis shows that the cancer risk is 2% 
at 10 years, 8% at 20 years, and 18% at 30 
years after IBD onset. Cancer risk begins to be 
significant 8 years after the onset of pancolitis 
(involvement of entire large intestine), or 12-15 
years after the onset of left-sided colitis.  
• Incidence of colorectal cancer in patients with 
active pancolitis is 19 times higher than the 
general population. 
• IBD is also associated with increased risk of 
extra-intestinal cancers. 
 
• Lynch syndrome is associated with 
80% of risk of developing colorectal 
carcinoma. It also shows an increased 
risk of endometrial carcinoma (33%), 
ovarian carcinoma (5%), and cancers of 
small bowel, stomach, upper urinary 
tract, and brain. 
• Eventually, all FAP patients will 
develop colorectal cancer from the 
adenomas usually by age 40. Therefore, 
patients with FAP must have the colon, 
and sometimes the rectum, removed to 
prevent CRCs. FAP is also associated 
with increased risk of extra-intestinal 
cancers. 
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Surveillance 
recommendations 
• In England, the NHS offers two types of 
bowel cancer screening to adults 
registered with a GP [72]: 1) All men and 
women aged 60-74 are invited to carry 
out a fecal occult blood test and every 
two years, they are sent a home test kit, 
which is used to collect a stool sample.  
2) An additional one-off test called bowel 
scope screening is gradually being 
introduced in England. This is offered to 
men and women at the age of 55. 
Moreover, an appropriate colonoscopic 
surveillance strategy should be offered to 
people with adenomas based on their risk 
of developing colorectal cancer as 
determined at initial adenoma removal.  
• American Cancer Society [73] 
recommends men and women, starting at 
age 50, at average risk for developing 
colorectal cancer should regularly use 
fecal occult blood test, colonoscopy or 
double-contrast barium enema to detect 
polyps or cancers. People at increased or 
high risk will need to start colorectal 
cancer screening before age 50 and/or be 
screened more often. 
 
• American Gastroenterological Association 
(AGA) [36] and European Crohn’s and Colitis 
Organization (ECCO) [40] recommend that 
initial surveillance colonoscopy begin after 8 
years of colitis or from the time of diagnosis of 
primary sclerosing cholangitis, at which time 
random biopsies or targeted colorectal biopsies 
should be performed.  
• British Society of Gastroenterology (BSG) [41] 
recommends beginning surveillance 
colonoscopy after 10 years of colitis, with 
chromoendoscopy as the preferred method.  
• For the ECCO and BSG, subsequent 
surveillance intervals are determined 
by stratifying patients into low-risk, 
intermediate-risk, and high-risk groups based 
on clinicopathological 
features. The overall clinical management 
depends on the histological findings and 
whether lesions are endoscopically 
resectable. 
• Guidelines and recommendations including 
educating patients in self check and 
preventative measurements like sun protection 
should be developed and applied in clinical 
practice to minimize the risk of IBD-related 
extra-intestinal malignancies. 
• Family members with Lynch syndrome 
should have surveillance colonoscopy 
every 1 to 2 years, starting from 20-25 
years, or 10 years before the youngest 
case in the immediate family.  
• Family members with FAP are 
recommended to have yearly 
colonoscopy to look for signs of 
adenomas, starting from age 10 to 12 
until the patient and physician 
determine that a colectomy is the best 
treatment. 
• Upper endoscopic surveillance is also 
recommended for patients with FAP 
and Lynch syndrome. 
Abbreviations: AGA: American Gastroenterological Association; APC: adenomatous polyposis coli; BSC: British Society of Gastroenterology; CRCs: colorectal carcinomas; 
ECCO: European Crohn’s and Colitis Organization; FAP: familial adenomatous polyposis; IBD: inflammatory bowel disease; MMR: mismatch repair. 
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Legend of the figures 
 
Figure 1 
Top panel shows ulcerative colitis with crypt abscess formation, crypt distortion and active 
inflammation but negative for dysplasia. Bottom panel shows features of quiescent colitis 
with focal crypt epithelial atypia, indefinite for low grade dysplasia. 
 
Figure 2 
Comparison of low grade dysplasia (left panel) and high grade dysplasia (right panel). Note 
the high nuclear to cytoplasmic ratio, nuclear hyperchromasia and loss of nuclear polarity in 
high grade dysplasia. 
 
Figure 3 
Histology of an endoscopic mucosal resection specimen showing dysplasia-associated 
lesion/mass (DALM). The large bowel mucosa is thickened and composed of dysplastic 
glands showing mixed low and high grade dysplasia. Background chronic inflammation is 
present. 
 
Figure 4 
Colectomy specimen from a patient with ulcerative colitis showing the junction of diseased 
and non-diseased large bowel. Due to marked inflammation and mucosal distortion, it is hard 
to identify the dysplastic or early cancer lesions. This explains why the diagnosis of colitis-
associated dysplasia and early cancer is difficult. 
 
Figure 5 
An advanced neoplastic lesion with central ulceration seen endoscopically (top panel). 
Biopsies show invasive adenocarcinoma (bottom panel). 
 
Figure 6 
Top panel shows primary sclerosing cholangitis (PSC). An intrahepatic bile duct is destroyed 
by chronic inflammation with surrounding laminated fibrosis. Bottom panel shows a 
cholangiocarcinoma arising on a background of PSC. 
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